|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-3-21
|
|
pubmed:abstractText |
Platelet aggregation is now believed to be mediated by fibrinogen binding to activated GP IIb/IIIa. Antigen binding site of mouse anti-human GP IIb/IIIa monoclonal antibody 7E3, which can inhibit fibrinogen binding to activated human platelet GP IIb/IIIa, was combined with constant region of human IgG to reduce immunogenicity. Monovalent Fab of this mouse-human chimeric antibody named abciximab effectively reduced the onset of cardiovascular accidents when administered in combination with heparin and aspirin in patients undergoing coronary interventions. Although several anti-GP IIb/IIIa other than monoclonal antibodies were developed, clinical efficiency of abciximab is still superior to other agents while its effects on preventing myocardial infarction in unstable angina patients are uncertain.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0047-1852
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
492-6
|
|
pubmed:dateRevised |
2011-7-27
|
|
pubmed:meshHeading |
pubmed-meshheading:11904964-Angina, Unstable,
pubmed-meshheading:11904964-Angioplasty, Balloon, Coronary,
pubmed-meshheading:11904964-Animals,
pubmed-meshheading:11904964-Antibodies, Monoclonal,
pubmed-meshheading:11904964-Clinical Trials as Topic,
pubmed-meshheading:11904964-Combined Modality Therapy,
pubmed-meshheading:11904964-Coronary Disease,
pubmed-meshheading:11904964-Humans,
pubmed-meshheading:11904964-Immunoglobulin Fab Fragments,
pubmed-meshheading:11904964-Mice,
pubmed-meshheading:11904964-Myocardial Infarction,
pubmed-meshheading:11904964-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:11904964-Recombinant Fusion Proteins
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
[New therapy with monoclonal antibodies--abciximab, chimeric anti-GP IIb/IIIa antibody].
|
|
pubmed:affiliation |
Division of Cardiology, Department of Medicine, Tokai University School of Medicine.
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|
